Plasma Resilience: Europe's Lifeline
When considering medical breakthroughs, human plasma is often overlooked. However, this protein-rich liquid, making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Europe's plasma supply chain is extremely vulnerable, as it relies on human donations. Unlike lab-produced therapies, plasma-based treatments exist thanks to the generosity of real people. Over 12 million Europeans donate plasma annually, following rigorous safety standards set by EU Member States, the International Quality Plasma Program (IQPP), and the Plasma Protein Therapeutics Association (PPTA).
Despite this, nearly 40% of plasma used for European medicines is imported from the United States, highlighting the need to strengthen the continent's plasma resilience.
Each year, more than 12 million people across Europe donate plasma through a process governed by rigorous safety standards.
- 55% of blood is plasma
- 12 million Europeans donate plasma annually
- 40% of plasma used in European medicines is imported from the US
Author's summary: Europe's plasma supply chain is vulnerable and needs strengthening.